Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lübbert

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|October 5, 2001
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cellsC Nguyen, G Liang, T T Nguyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromesT Nösslinger, H Tüchler, U Germing, et al.
Blood|April 26, 2000
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implicationsT T Nguyen, A F Mohrbacher, Y C Tsai, et al.
Annals of Hematology|March 23, 2004
Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trialG Heil, J Krauter, A Raghavachar, et al.
British Journal of Haematology|October 29, 1998
Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AMLJ Krauter, W Peter, U Pascheberg, et al.
Annals of Hematology|October 18, 2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overloadF Nolte, B Höchsmann, A Giagounidis, et al.
Leukemia|May 20, 2005
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alphaY Jiang, Z-H Xue, W-Z Shen, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|October 5, 2001
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cellsC Nguyen, G Liang, T T Nguyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromesT Nösslinger, H Tüchler, U Germing, et al.
Blood|April 26, 2000
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implicationsT T Nguyen, A F Mohrbacher, Y C Tsai, et al.
Annals of Hematology|March 23, 2004
Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trialG Heil, J Krauter, A Raghavachar, et al.
British Journal of Haematology|October 29, 1998
Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AMLJ Krauter, W Peter, U Pascheberg, et al.
Annals of Hematology|October 18, 2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overloadF Nolte, B Höchsmann, A Giagounidis, et al.
Leukemia|May 20, 2005
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alphaY Jiang, Z-H Xue, W-Z Shen, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Pageof 12